Infinity Pharmaceuticals, Inc. (INFI)
After hours:
| Previous close | 0.5550 |
| Open | 0.5500 |
| Bid | 0.5300 x 1100 |
| Ask | 0.5700 x 900 |
| Day's range | 0.5300 - 0.5645 |
| 52-week range | 0.4600 - 2.8100 |
| Volume | |
| Avg. volume | 441,474 |
| Market cap | 48.345M |
| Beta (5Y monthly) | 1.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5190 |
| Earnings date | 14 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.38 |
- Business Wire
Infinity Pharmaceuticals to Participate in Piper Sandler 34th Annual Healthcare Conference
CAMBRIDGE, Mass., November 22, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will present and conduct 1-on-1 meetings with investors at the Piper Sandler 34th Annual Healthcare Conference taking place November 29 – December 1, 2022 in New York.
- Zacks
Down 44.4% in 4 Weeks, Here's Why Infinity (INFI) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Infinity (INFI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- Simply Wall St.
Infinity Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectations
Infinity Pharmaceuticals ( NASDAQ:INFI ) Third Quarter 2022 Results Key Financial Results Net loss: US$10.7m (flat on...
